S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
LON:RENE

ReNeuron Group Share Forecast, Price & News

GBX 102
+2.00 (+2.00 %)
(As of 03/5/2021 04:40 PM ET)
Add
Compare
Today's Range
100
Now: GBX 102
103.75
50-Day Range
100
MA: GBX 116.20
134
52-Week Range
70
Now: GBX 102
179
Volume246,236 shs
Average Volume326,503 shs
Market Capitalization£57.99 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in Phase IIb clinical trial for stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also developing CTX-derived exosomes, which are Nano-sized packages of information released by CTX cells. ReNeuron Group plc has a research agreement with U.S. biotechnology company in the discovery and development of novel gene silencing-based therapeutics. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
ReNeuron Group logo

Headlines

Reneuron Share News (RENE)
December 11, 2020 |  lse.co.uk
ReNeuron Group PLC Registered S (RQE1.SG)
October 10, 2020 |  au.finance.yahoo.com
ReNeuron Signs New Exosome Research Collaboration
June 25, 2020 |  finance.yahoo.com
ReNeuron Announces Exosome Research Collaboration
April 7, 2020 |  finance.yahoo.com
Edison issues update on ReNeuron Group (RENE)
February 10, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-38198400
Employees62
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£112,000.00
Cash FlowGBX 29.73 per share
Book ValueGBX 20.80 per share

Profitability

Miscellaneous

Market Cap£57.99 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.60 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
GBX 102
+2.00 (+2.00 %)
(As of 03/5/2021 04:40 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RENE News and Ratings via Email

Sign-up to receive the latest news and ratings for RENE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ReNeuron Group (LON:RENE) Frequently Asked Questions

What stocks does MarketBeat like better than ReNeuron Group?

Wall Street analysts have given ReNeuron Group a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ReNeuron Group wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were ReNeuron Group's earnings last quarter?

ReNeuron Group plc (LON:RENE) announced its quarterly earnings results on Monday, July, 20th. The company reported ($35.90) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($50.20) by $14.30.
View ReNeuron Group's earnings history
.

How has ReNeuron Group's stock been impacted by COVID-19?

ReNeuron Group's stock was trading at GBX 106 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RENE shares have decreased by 3.8% and is now trading at GBX 102.
View which stocks have been most impacted by COVID-19
.

Who are ReNeuron Group's key executives?

ReNeuron Group's management team includes the following people:
  • Mr. Olav Hellebo, CEO & Director (Age 56, Pay $397k)
  • Mr. Michael E. Hunt A.C.A., BSc, ACA, CFO, Company Sec. & Exec. Director (Age 58, Pay $247k)
  • Mr. Shaun Stapleton, Head of Regulatory Affairs and VP of Regulatory Affairs & Pharmacovigilance
  • Dr. Richard L. Beckman, Chief Medical Officer

Who are some of ReNeuron Group's key competitors?

What other stocks do shareholders of ReNeuron Group own?

What is ReNeuron Group's stock symbol?

ReNeuron Group trades on the London Stock Exchange (LON) under the ticker symbol "RENE."

How do I buy shares of ReNeuron Group?

Shares of RENE and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is ReNeuron Group's stock price today?

One share of RENE stock can currently be purchased for approximately GBX 102.

How much money does ReNeuron Group make?

ReNeuron Group has a market capitalization of £57.99 million and generates £112,000.00 in revenue each year.

How many employees does ReNeuron Group have?

ReNeuron Group employs 62 workers across the globe.

What is ReNeuron Group's official website?

The official website for ReNeuron Group is www.reneuron.com.

Where are ReNeuron Group's headquarters?

ReNeuron Group is headquartered at Pencoed Business Park, BRIDGEND, CF35 5HY, United Kingdom.

How can I contact ReNeuron Group?

ReNeuron Group's mailing address is Pencoed Business Park, BRIDGEND, CF35 5HY, United Kingdom. The company can be reached via phone at +44-20-38198400.


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.